News
Novo Nordisk ousts boss as Ozempic maker battles slump
Novo Nordisk has ousted chief executive Lars Fruergaard Jørgensen as the maker of pioneering obesity drug Ozempic battles a slump in profit growth, declining market share and a plunging stock price. Shares in the drugmaker have fallen more than 50 per cent in the past 12 months,
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...
When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...
10hon MSN
Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its ...
News Nation on MSN12h
CEO of Novo Nordisk, maker of Ozempic and Wegovy, stepping downThe company pointed to "recent market challenges" and "share price decline" as reasons for Lars Fruergaard Jørgensen's ...
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...
Novo Nordisk’s CEO Lars Fruergaard Jørgensen will stand down as the chief of the Danish pharma giant following increased ...
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback